AMENDMENTS

This listing replaces all prior versions and listings of claims in the application.

1. (Previously Presented) A stable liquid medical formulation (A) that comprises a therapeutically effective amount of an antibody against CD40, sorbitol as isotonizing agent, a polysorbate as surfactant and glutamate as sole buffer and (B) that has a pH between 4.0 and 6.0.

2. (Previously Presented) The stable liquid medical formulation according to claim 1, wherein the concentration of the buffer is between 1 mM and 50 mM.

3. (Canceled)

4. (Previously Presented) The stable liquid medical formulation according to claim 1, which contains no salt as an isotonizing agent.

5-6. (Canceled)

7. (Previously Presented) The stable liquid medical formulation according to claim 1, having an osmotic pressure between 250 mOsm and 350 mOsm.

8. (Canceled)

9. (Previously Presented) The stable liquid medical formulation according to claim 1, wherein the surfactant is polysorbate 80.

10. (Previously Presented) The stable liquid medical formulation according to claim 1, wherein the surfactant is present in a concentration between 0.02 mg/mL and 0.10 mg/mL.

11. (Previously Presented) The stable liquid medical formulation according to claim 1, wherein the antibody against CD40 is a human antibody, a humanized antibody, or a chimeric antibody.

12. (Previously Presented) The stable liquid medical formulation according to claim 1, wherein the antibody against CD40 is a monoclonal antibody.

13. (Previously Presented) The stable liquid medical formulation according to claim 1, wherein the antibody against CD40 is IgG.

14. (Previously Presented) The stable liquid medical formulation according to claim 13, wherein the IgG is any one of IgG1, IgG2, or IgG4.

15-17. (Canceled)

18. (Previously Presented) The stable liquid medical formulation according to claim 1, wherein the antibody against CD40 is present in a concentration between approximately 1 and 200 mg/mL.

19-20. (Canceled)

21. (Previously Presented) The stable liquid medical formulation comprising:

(a) a therapeutically effective amount of an antibody against CD40;

(b) sorbitol as isotonizing agent;

(c) a polysorbate as surfactant; and

(d) at least one stabilizing agent selected from the group consisting of glycine, methionine, cysteine hydrochloride, leucine, lysine hydrochloride, arginine hydrochloride, aspartic acid, ascorbic acid, EDTA, and salts thereof,

with glutamate as sole buffer, the formulation having a pH between 4.0 and 6.0.

22-23. (Canceled)